Articles from Kynexis

Novartis Venture Fund joins Kynexis’ existing investor syndicate, supporting the Company’s vision of becoming a leading late-stage cognition company

Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2 clinical trial in patients with cognitive impairment associated with schizophrenia

KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1 study in healthy volunteers

NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB). Committed to accelerating groundbreaking research and development initiatives, the SAB comprises globally renowned experts in neuroscience, genetics, as well as drug discovery and development. The SAB will work with the Kynexis leadership team to advance KYN-5356, a first-in-class small molecule KAT-II inhibitor in development for the treatment of cognitive impairment associated with schizophrenia (CIAS).

KYN-5356 is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathway

- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia